Creative BioMart to Present at BPS 2025 Annual Meeting | February 15-19, 2025

Recombinant Mouse Tnfrsf18 Protein, Myc/DDK-tagged

Cat.No. : Tnfrsf18-6547M
Product Overview : Purified recombinant protein of mouse full-length tumor necrosis factor receptor superfamily, member 18 (Tnfrsf18), with C-terminal MYC/DDK tag, expressed in HEK293T cells.
  • Specification
  • Gene Information
  • Related Products
  • Download
Description : Receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. Mediated NF-kappa-B activation via the TRAF2/NIK pathway.
Source : HEK293T
Species : Mouse
Tag : Myc&DDK
Molecular Mass : 25.8 kDa
Purity : > 80% as determined by SDS-PAGE and Coomassie blue staining
Stability : Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
Storage : Store at -80 centigrade after receiving vials.
Concentration : >50 μg/mL as determined by microplate BCA method
Storage Buffer : 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.
Gene Name : Tnfrsf18 tumor necrosis factor receptor superfamily, member 18 [ Mus musculus (house mouse) ]
Official Symbol : Tnfrsf18
Synonyms : TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18; glucocorticoid-induced TNFR-related protein; AITR; Gitr
Gene ID : 21936
mRNA Refseq : NM_009400
Protein Refseq : NP_033426
UniProt ID : O35714

Not For Human Consumption!

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
12/20/2021

    This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

    03/05/2020

      Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

      10/01/2017

        The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

        Q&As (5)

        Ask a question
        What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment? 12/20/2022

        Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

        Are there any approved TNFRSF18-targeted therapies for cancer treatment? 06/29/2019

        As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

        Are there potential side effects associated with TNFRSF18-targeted therapies? 12/30/2018

        Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

        How can TNFRSF18-targeted therapies potentially improve cancer outcomes? 05/05/2018

        TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

        Can TNFRSF18-targeted therapies be used in combination with other immunotherapies? 05/20/2016

        Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.

        Ask a Question for All Tnfrsf18 Products

        Required fields are marked with *

        My Review for All Tnfrsf18 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2025 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends